Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 24, 2025

PE anti-human CD3

RRID:AB_314044
Type: Antibody

Proper Citation

(BioLegend Cat# 300308, RRID:AB_314044)

Antibody Information

URL: http://antibodyregistry.org/AB_314044

Proper Citation: (BioLegend Cat# 300308, RRID:AB_314044)

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: PE anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_314044

Vendor: BioLegend

Catalog Number: 300308

Alternative Catalog Numbers: 300307

Record Creation Time: 20231110T042108+0000

Record Last Update: 20241115T081622+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for PE anti-human CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

De Leo A, et al. (2024) Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity, 57(5), 1105.

Shang L, et al. (2024) Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers. Cell reports. Medicine, 5(7), 101648.

Zhang Y, et al. (2024) Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. Cell reports methods, 4(9), 100843.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell, 187(11), 2703.

Shen J, et al. (2024) Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. Cell stem cell, 31(7), 1003.

Tian M, et al. (2023) Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell reports. Medicine, 4(10), 101212.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 185(9), 1521.

Park JA, et al. (2021) Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. Journal for immunotherapy of cancer, 9(5).

Jackson-Jones LH, et al. (2020) Stromal Cells Covering Omental Fat-Associated Lymphoid Clusters Trigger Formation of Neutrophil Aggregates to Capture Peritoneal Contaminants. Immunity, 52(4), 700.

Park JA, et al. (2020) GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. Journal of hematology & oncology, 13(1), 172.

Brown CC, et al. (2019) Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity. Cell, 179(4), 846.

Usmani SM, et al. (2019) HIV-1 Balances the Fitness Costs and Benefits of Disrupting the Host Cell Actin Cytoskeleton Early after Mucosal Transmission. Cell host & microbe, 25(1), 73.